•  
  •  
 

Turkish Journal of Biology

Abstract

Background/aim: Osteosarcoma, a primary malignant bone tumor, is challenging to treat due to its aggressive nature and limited therapies. Resveratrol (RES), a natural polyphenol, has potential anticancer properties. Hence, we investigated RES’s impact on osteosarcoma cells, focusing on triosephosphate isomerase (TPI) and related mechanisms.

Materials and methods: RES was applied to osteosarcoma (SaOS-2) and healthy fetal osteoblast (hFOB 1.19) cells for 48 h, and cell viability was measured by SRB assay. The mode of cell death was examined using Hoechst 33342/annexin V/propidium iodide. TPI and methylglyoxal (MG) enzyme levels were determined by ELISA. The effect of RES on the mineralization mechanism was investigated using the Alizarin Red-S method.

Results: Viability assays showed that RES significantly reduced SaOS-2 cell viability, while sparing hFOB 1.19 cells. RES treatment decreased TPI levels in SaOS-2 cells and induced MG accumulation, correlating with reduced TPI. RES also triggered apoptosis and reduced mineralization in osteosarcoma cells, affecting osteogenic differentiation.

Conclusion: RES shows potential as a therapeutic agent targeting the glycolytic metabolism and apoptotic pathways in osteosarcoma cells and warrants further investigation for osteosarcoma treatment.

Author ORCID Identifier

GONCA TUNA: 0000-0003-2567-8056

SİBEL ÇINAR ASA: 0000-0002-3064-6449

ELİF ERTÜRK: 0000-0001-7668-796X

YAREN YILDIZ: 0000-0002-0004-982X

FERDA ARI: 0000-0002-6729-7908

DOI

10.55730/1300-0152.2737

Keywords

Resveratrol, osteosarcoma, triosephosphate isomerase, methylglyoxal, glycolysis, osteogenic differentiation

First Page

198

Last Page

208

Publisher

Scientific and Technological Research Council of Türkiye (TUBITAK)

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Download

Share

COinS